9907BHV3500-203Open (affiliates only)BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental OxygenNCT04346615IndustryAdultTreatmentOtherKumar, PrincyGeorgetown University Medical Center : Katherine Fan; Lombardi Comprehensive Cancer Center : Katherine FanGUMC Medicine Infectious Disease- 14906Katherine FanKatherine Fankff13@georgetown.edu
2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>